Cargando…

Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting

BACKGROUND: Non-nucleoside reverse transcriptase inhibitor (NNRTI) with stavudine and lamivudine is widely used as the first-line antiretroviral therapy (ART) in resource-limited settings. Lipodystrophy is common and options for switching ART regimen are limited; this situation can lead to patients&...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sungkanuparph, Somnuek, Kiertiburanakul, Sasisopin, Apisarnthanarak, Anucha, Malathum, Kumthorn, Watcharananan, Siriorn, Sathapatayavongs, Boonmee
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211500/ https://www.ncbi.nlm.nih.gov/pubmed/18031583 http://dx.doi.org/10.1186/1742-6405-4-26

Ejemplares similares

A Model and Risk Score for Predicting Nevirapine-Associated Rash among HIV-infected Patients: In Settings of Low CD4 Cell Counts and Resource Limitation
por: Kiertiburanakul, Sasisopin, et al.
Publicado: (2009)

Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay
por: Kiertiburanakul, Sasisopin, et al.
Publicado: (2016)

Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand
por: Sungkanuparph, Somnuek, et al.
Publicado: (2012)

Prevalence of HIV infection, access to HIV care, and response to antiretroviral therapy among partners of HIV-infected individuals in Thailand
por: Kiertiburanakul, Sasisopin, et al.
Publicado: (2018)

Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Petchkum, Porkaew, et al.
Publicado: (2019)

Microbial epidemiology and risk factors for relapse in gram-negative bacteria catheter-related bloodstream infection with a pilot prospective study in patients with catheter removal receiving short-duration of antibiotic therapy
por: Surapat, Bhitta, et al.
Publicado: (2020)

Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study
por: Srichatrapimuk, Sirawat, et al.
Publicado: (2023)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate
por: Phuphuakrat, Angsana, et al.
Publicado: (2022)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2009)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia
por: Jiamsakul, Awachana, et al.
Publicado: (2014)

Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
por: Geretti, Anna Maria, et al.
Publicado: (2013)

Anti–SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report
por: Boongird, Sarinya, et al.
Publicado: (2021)

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature
por: Achhra, Amit C, et al.
Publicado: (2013)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

431 Incidence, Burden and Cost Analysis of CMV Reactivation after Use of Anti-Thymocyte Globulin in Resource-Limited Setting
por: Chitasombat, Maria N., et al.
Publicado: (2014)

Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine
por: Boongird, Sarinya, et al.
Publicado: (2021)

Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
por: Boongird, Sarinya, et al.
Publicado: (2022)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
por: Ariën, Kevin K, et al.
Publicado: (2011)

Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases
por: Marfatia, Yogesh S., et al.
Publicado: (2014)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
por: Vanangamudi, Murugesan, et al.
Publicado: (2023)

The Association of HLA-B*35 and GSTT1 Genotypes and Hepatotoxicity in Thai People Living with HIV
por: Chanhom, Noppadol, et al.
Publicado: (2022)

1579. Incidence and Predicting Factors of Opportunistic Infections after Initiation of Antiretroviral Therapy: A Retrospective Cohort Study
por: Wongkittipong, Prapon, et al.
Publicado: (2023)

The Impact of Combination Antiretroviral Therapy and its Interruption on Anxiety, Stress, Depression and Quality of Life in Thai Patients
por: Nüesch, Reto, et al.
Publicado: (2009)

Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients
por: Bruminhent, Jackrapong, et al.
Publicado: (2022)

SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)
por: Bruminhent, Jackrapong, et al.
Publicado: (2022)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance
por: Galilee, Meytal, et al.
Publicado: (2018)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
por: Dąbrowska, Aleksandra, et al.
Publicado: (2018)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
por: Stachowicz-Kuśnierz, Anna, et al.
Publicado: (2023)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
por: Fernandes, Lívia da Rocha, et al.
Publicado: (2023)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
por: Orrell, Catherine, et al.
Publicado: (2015)

The Impact of Timing of Antiretroviral Therapy Initiation on Retention in Care, Viral Load Suppression and Mortality in People Living with HIV: A Study in a University Hospital in Thailand
por: Eamsakulrat, Pruke, et al.
Publicado: (2022)

Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
por: Manosuthi, Weerawat, et al.
Publicado: (2007)

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors
por: Yin, Dwight E., et al.
Publicado: (2020)

Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition
por: Jones, R. Brad, et al.
Publicado: (2008)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Schauer, Grant, et al.
Publicado: (2013)

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
por: Usach, Iris, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2i503eatepv0tmfni1h2ano6q0